AGRX Agile Therapeutics Inc.

-0.02  -5%
Previous Close 0.35
Open 0.36
Price To Book 0.44
Market Cap 11602349
Shares 34,377,329
Volume 687,303
Short Ratio 0.95
Av. Daily Volume 2,041,433

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 18992182
  2. 8-K - Current report 18990358
  3. 8-K - Current report 18966723
  4. 8-K - Current report 18945276
  5. 8-K - Current report 18912114

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued 2013. Further CRL issued December 22, 2017. Noted May 18, 2018 that FDA will require further trials for resubmission to take place.
Contraceptive patch

Latest News

  1. Does Agile Therapeutics Inc (NASDAQ:AGRX) Fall With The Market?
  2. Today’s Research Reports on Stocks to Watch: Agile Therapeutics and BioPharmX
  3. New Growth Opportunities Jump for 3 Biotech Stocks in 2018
  4. Consolidated Research: 2018 Summary Expectations for Internap, Approach Resources, Agile Therapeutics, Town Sports International, Dicerna Pharmaceuticals, and Cott — Fundamental Analysis, Key Performance Indications
  5. AGRX: Formal Dispute Resolution Continues to Office of New Drugs…
  6. Agile Therapeutics: 2Q Earnings Snapshot
  7. Agile Therapeutics Reports Second Quarter 2018 Financial Results
  8. Complimentary Technical Snapshots on Akorn and Three More Generic Drugs Stocks
  9. FDA’s Office of Drug Evaluation III Denies Agile Therapeutics, Inc.’s Initial Formal Dispute Resolution Request
  10. Free Technical Research on Akorn and Three More Generic Drugs Equities
  11. AGRX: Files Formal Dispute Resolution with the FDA
  12. Benzinga's Daily Biotech Pulse: EDAP Device Gets FDA Nod, Ampliphi Presents Positive Data, Agile To Cut Jobs
  13. AGRX: Determining a Path Forward Following Receipt of Meeting Minutes
  14. Today’s Research Reports on Stocks to Watch: Agile Therapeutics and Arrowhead Pharmaceuticals
  15. Agile Therapeutics sinks after FDA feedback on contraceptive
  16. Corium International (CORI) Q2 2018 Earnings Conference Call Transcript
  17. AGRX: Waiting on Meeting Minutes from FDA; Planning for 2Q18 Twirla® NDA Resubmission